Form 4: Arcellx Director Kavita Patel Reports Stock Option Transactions

Arcellx, Inc. Director Kavita Patel has reported transactions related to stock options following the company's merger with Gilead Sciences, Inc.

Summary

• This filing is a Form 4, reporting changes in beneficial ownership of securities.
• Director Kavita Patel reported transactions related to stock options on April 28, 2026.
• These transactions are a result of the merger between Arcellx, Inc. and Gilead Sciences, Inc., effective February 22, 2026.
• Company stock options were canceled and converted into a cash payment and contingent value rights.
• The cash payment is calculated as the excess of the closing amount ($115 per share) over the option's exercise price, multiplied by the number of shares subject to the option.
• Each option share also converted into one contractual contingent value right.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on the mechanics of stock option conversion due to a merger, rather than new financial performance or strategic shifts.

Positives

• Director Kavita Patel's stock options were converted into a cash payment and contingent value rights, providing immediate value realization.
• The merger with Gilead Sciences, Inc. represents a significant event for Arcellx, Inc. shareholders and stakeholders.

Negatives

• All outstanding Arcellx stock options, regardless of vesting status, were canceled as part of the merger.
• The value received for options is dependent on the exercise price being less than the $115 closing amount, meaning options with exercise prices at or above this threshold would not yield a cash payment.

Risks

• The value of the contingent value rights is not specified and will depend on future events and milestones related to Arcellx's products.
• The filing does not detail the specific exercise prices of all options held by Ms. Patel, making it difficult to ascertain the exact cash payout.

Future Outlook

The future outlook for the contingent value rights is tied to the success of Arcellx's product development and commercialization efforts, which are not detailed in this specific filing.

Management Comments

• The filing details the conversion of stock options into cash payments and contingent value rights as per the merger agreement.
• The explanation of responses clarifies the mechanics of the option conversion: cash payment is (Closing Amount - Exercise Price) * Number of Shares, plus one contingent value right per share.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome for executive and director stock options following a merger or acquisition, where existing equity awards are cashed out or converted into rights related to the acquiring entity or a contingent value mechanism.

Stakeholder Impact

• Shareholders: The merger with Gilead Sciences, Inc. is a significant event, potentially leading to increased value and access to resources.
• Option Holders (including Director Kavita Patel): Will receive cash payments and contingent value rights, providing a realization of value from their options.
• Employees: May see changes in their employment terms and equity compensation structures under the new ownership by Gilead Sciences, Inc.

Next Steps

• Shareholders and option holders will receive cash payments and contingent value rights as per the merger agreement.
• Further information regarding the contingent value rights will likely be disclosed in future filings or company communications.

Key Dates

Keywords

Form 4, Arcellx, ACLX, Kavita Patel, Stock Options, Merger, Gilead Sciences, Beneficial Ownership, SEC Filing, Insider Trading